ANNUAL REPORT 2012 - TiGenix

More documents

Recommendations

Info

7.5. Board of Directors and Board committees Composition of the Board of Directors On the date of publication of this registriation document, the Board of Directors consists of the following nine (9) members. Name Age (as per December 31, 2012) Innosté SA, represented 63 Chairman / by Jean Stéphenne (5) Independent director Gil Beyen BVBA (2) , represented by Gil Beyen 51 Managing Director (executive) / CBO Eduardo Bravo Fernández de Araoz (3) 47 Managing Director (executive) / CEO Willy Duron (4) 67 Independent director Greig Biotechnology Global Consulting, Inc., represented by Russell Greig (5) 60 Independent director Eduard Enrico 67 Independent Holdener (3) director Ysios Capital Partners SGECR SA (6) , represented by Joël Jean-Mairet R&S Consulting BVBA (3) , represented by Dirk Reyn LRM Beheer NV (3) , represented by Nico Vandervelpen 41 Director (non-executive) 51 Independent director 38 Director (non-executive) Position Term (1) Professional Address 2016 Avenue Alexandre 8, 1330 Rixensart, Belgium 2015 Boetsenberg 20, 3053 Haasrode, Belgium 2015 Romeinse straat 12, 3001 Leuven, Belgium 2015 Oude Pastoriestraat 2, 3050 Oud-Heverlee, Belgium 2016 1241 Karen Lane, Wayne, PA 19087, USA 2015 Buchenrain 6, 4106 Therwil, Switzerland 2015 Calle Baldiri Reixac 10- 12, Parc Cientific de Barcelona, Barcelona, Spain 2015 Populierstraat 4, 1000 Brussel, Belgium 2015 Kempische Steenweg 555, 3500 Hasselt, Belgium (1) The term of the mandates of the directors will expire immediately after the annual shareholders’ meeting held in the year set forth next to the director’s name. (2) First appointed by the shareholders’ meeting on February 26, 2007. Appointment renewed on April 20, 2011 and on April 26, 2011 with effect as of May 3, 2011. (3) First appointed on April 26, 2011 with effect as of May 3, 2011. (4) First appointed by the shareholders’ meeting on February 26, 2007. Appointment renewed on April 20, 2011 and on April 26, 2011 with effect as of May 3, 2011. Willy Duron resigned as Chairman of the Board of Directors on September 19, 2012 and was replaced as Chairman by Innosté SA, represented by Jean Stéphenne. (5) First appointed on a provisional basis by the meeting of the Board of Directors on September 19, 2012, in order to replace Ms. Mounia Chaoui-Roulleau (who had been appointed director herself on January 18, 2012 in replacement of Ventech S.A.) and Mr. Koenraad Debackere, both having resigned effective as of September 19, 2012. The shareholders’ meeting of February 26, 2013 has confirmed their appointment. (6) On April 26, 2011 with effect as of May 3, 2011, Mr. Joël Jean-Mairet was first appointed as a director. It was, however, the intention of Mr. Jean-Mairet to be appointed as permanent representative of Ysios Capital Partners SGECR SA. He therefore resigned as a director on May 4, 2011 and the board of directors decided on May 4, 2011 to appoint Ysios Capital Partners SGECR SA, represented by Mr. Jean-Mairet, as a director in order to replace Mr. Jean-Mairet until the shareholders’ meeting of the Company of April 20, 2012 which confirmed its appointment. 180 TiGenix I annual report 2012
Functioning of the Board of Directors in 2012 In 2012, the Board of Directors met 13 times. Individual presence of the members of the Board of Directors in 2012 Name Number of meetings attended Gil Beyen BVBA, represented by Gil Beyen 10 Eduardo Bravo 11 Mounia Chaoui-Roulleau 6 Ventech S.A., represented by Mounia Chaoui-Roulleau 1 Koenraad Debackere 2 Willy Duron 11 Greig Biotechnology Global Consulting, Inc., represented by Russell Greig 2 Eduard Enrico Holdener 9 Ysios Capital Partners SGECR SA, represented by Joël Jean-Mairet 9 R&S Consulting BVBA, represented by Dirk Reyn 9 Innosté SA, represented by Jean Stéphenne 2 LRM Beheer NV, represented by Nico Vandervelpen 10 Audit Committee The following directors are member of the audit committee : Name Willy Duron Innosté SA, represented by Jean Stéphenne (1) LRM Beheer NV, represented by Nico Vandervelpen Position Chairman of the audit committee; Independent Director Member of the audit committee; Chairman of the Board of Directors; Independent Director Member of the audit committee; Director (non-executive) (1) Innosté SA, represented by Jean Stéphenne, has been a member of the audit committee since September 19, 2012, replacing Eduard Enrico Holdener. The audit committee met twice in 2012. All members of the audit committee were present at both meetings. As proof of the independence and expertise of the audit committee in the area of audit and accountancy, and as required by Article 96, §1, 9° of the Companies Code, we refer to the biographies of the members of the audit committee as set out below : Willy Duron : Independent Director Mr. Willy Duron has been an independent board member of TiGenix since February 2007. He was the Company’s Chairman from September 2007 to September 2012. He started his career at ABB Verzekeringen in 1970, becoming a member of the executive committee in 1984. Mr. Duron holds a MSc degree in mathematics from the University of Gent and a MSc degree in actuarial sciences from the Katholieke Universiteit Leuven. He currently is a member of the board of directors of Ravago NV, Vanbreda Risk & Benefits NV, Universitaire Ziekenhuizen Leuven, Universitair Centrum St Jozef Kortenberg, Agfa-Gevaert NV and 181
Page 1 and 2:
ANNUAL REPORT 2012
Page 3 and 4:
9. MAJOR SHAREHOLDERS 103 9.1. OVER
Page 5 and 6:
There can be no assurance that TiGe
Page 7 and 8:
educing their ultimate value to the
Page 9 and 10:
eimbursement in certain instances s
Page 11 and 12:
or the relevant manufacturing proce
Page 13 and 14:
In recent years, it expanded its op
Page 15 and 16:
making this change may be costly an
Page 17 and 18:
TiGenix’s development stage produ
Page 19 and 20:
qualified employees and consultants
Page 21 and 22:
1. Introduction Annual report 2012
Page 23 and 24:
2. Persons Responsible for the Cont
Page 25 and 26:
4. Selected Financial Information Y
Page 27 and 28:
5.3. ORGANISATIONAL STRUCTURE TiGen
Page 29 and 30:
Date Transaction Number and class o
Page 31 and 32:
Date Transaction Number and class o
Page 33 and 34:
(12) The shares were subscribed to
Page 35 and 36:
5.5. DESCRIPTION OF RIGHTS AND BENE
Page 37 and 38:
Formalities to attend the sharehold
Page 39 and 40:
amendments to the Articles of Assoc
Page 41 and 42:
the existing shareholders have a pr
Page 43 and 44:
Issue date Term Number of warrants
Page 45 and 46:
6. Business Overview Most of the in
Page 47 and 48:
6.2. COMPETITIVE STRENGTHS The Comp
Page 49 and 50:
6.3. IMPORTANT EVENTS IN THE DEVELO
Page 51 and 52:
6.3.5. Funding history Since its in
Page 53 and 54:
non-weight bearing area of the join
Page 55 and 56:
6.4.5. Commercial launch ChondroCel
Page 57 and 58:
und Behandlungsmethode”) in sever
Page 59 and 60:
Therapeutics (product Hyalograft C)
Page 61 and 62:
Different routes of administration
Page 63 and 64:
Clinical development In January 201
Page 65 and 66:
evenues from this pipeline within t
Page 67 and 68:
that the average cost of treatment
Page 69 and 70:
TiGenix has obtained cGMP status fo
Page 71 and 72:
Biologics for treatment of Rheumato
Page 73 and 74:
of the patents and patent applicati
Page 75 and 76:
- “Marker genes for use in the id
Page 77 and 78:
manufacturing process and therapeut
Page 79 and 80:
Invalidation of US patent US6777231
Page 81 and 82:
7. Corporate Governance 7.1. GENERA
Page 83 and 84:
7.2.3. Independent directors As to
Page 85 and 86:
7.2.4. Composition of the Board of
Page 87 and 88:
of Ravago NV, Vanbreda Risk & Benef
Page 89 and 90:
Litigation statement concerning the
Page 91 and 92:
As proof of the independence and an
Page 93 and 94:
for their healthcare and biotechnol
Page 95 and 96:
7.5. SCIENTIFIC ADVISORY BOARD AND
Page 97 and 98:
As of the date of publication of th
Page 99 and 100:
(rounded down to the nearest intege
Page 101 and 102:
usiness at customary market conditi
Page 103 and 104:
9. Major Shareholders 9.1. OVERVIEW
Page 105 and 106:
10. Financial Statements : General
Page 107 and 108:
11. Consolidated Financial Statemen
Page 109 and 110:
11.3. CONSOLIDATED STATEMENT OF CAS
Page 111 and 112:
The consolidated financial statemen
Page 113 and 114:
11.5.2.2. Basis of consolidation Th
Page 115 and 116:
are provided and costs are incurred
Page 117 and 118:
of interest on the remaining balanc
Page 119 and 120:
Deferred tax assets and liabilities
Page 121 and 122:
- Partnering of Cx601 (i.e. finding
Page 123 and 124:
The Group is mainly exposed to the
Page 125 and 126:
fiscal year 2010, reference is made
Page 127 and 128:
Sales and marketing expenses Years
Page 129 and 130: The number of employees in the R&D
Page 131 and 132: Analysis of profit/(loss) for the p
Page 133 and 134: (8) Disposal group held for sale Th
Page 135 and 136: (10) Property, plant and equipment
Page 137 and 138: The decrease of stock in 2012 compa
Page 139 and 140: dividends will be based upon the Co
Page 141 and 142: alance. As a consequence, the Compa
Page 143 and 144: (23) Other current liabilities The
Page 145 and 146: TiGenix SAU - Stock options Prior t
Page 147 and 148: (25) Business combination Descripti
Page 149 and 150: (26) Related party transactions Tra
Page 151 and 152: (28) Commitments and contingencies
Page 153 and 154: (30) Consolidation scope Name Subsi
Page 155 and 156: We believe that the audit evidence
Page 157 and 158: assets and liabilities, its financi
Page 159 and 160: the results of its operations and c
Page 161 and 162: 12.2. STATUTORY BALANCE SHEET 2010-
Page 163 and 164: The value of receivables is reduced
Page 165 and 166: 13. Annual Report of the Board of D
Page 167 and 168: 2013. The facility will provide the
Page 169 and 170: year ended December 31, 2011, and T
Page 171 and 172: Operating result (EBIT) and net res
Page 173 and 174: Statement of financial position The
Page 175 and 176: - The total personnel costs of EUR
Page 177 and 178: - TiGenix may fail in successfully
Page 179: continue as a going concern and to
Page 183 and 184: The nomination and remuneration com
Page 185 and 186: Apart from the above remuneration f
Page 187 and 188: Shares and warrants held by indepen
Page 189 and 190: - Long-term incentive plan : warran
Page 191 and 192: Shares and warrants held by executi
Page 193 and 194: - identifying and implementing busi
Page 195 and 196: actual bonus equal to 78 % of her p
Page 197 and 198: was reduced to a half-time role com
Page 199 and 200: 14. Business and Financial Update a
Page 201 and 202: Financial results for the full year
Page 203 and 204: 15. Available Documents The Company
Page 205 and 206: Title Country Application number Ce
Page 207 and 208: Title Country Application number Is
Page 209 and 210: Country Trademark Classes USA CELLE
show all

ANNUAL REPORT 2012 - TiGenix

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?